Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SuperSonic Imagine’s Aixplorer® Ultimate Highlighted at American Institute of Ultrasound in Medicine Meeting in New York


Posted on: 21 Mar 18

Aix-en-Provence, France, March 21, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that it will highlight its premium ultrasound platform at the American Institute of Ultrasound in Medicine (AIUM) 2018 meeting in New York City, March 24-28. The Aixplorer Ultimate, the only UltraFast™ ultrasound system, offers enhanced performance, workflow and efficiency, as well as a combination of impeccable image quality and important ultrasound advances. The system’s elegant new look and user interface make it simpler and less fatiguing to use. The Ultimate is faster as well, with a computation power more than 4.5 times faster and 20% more energy efficient than its predecessor.

“We are very excited to share the Aixplorer Ultimate with attendees at AIUM 2018,” said SuperSonic Imagine CEO Michèle Lesieur. “Aixplorer Ultimate is the result of 8 years of research and development. This is a much more reliable, faster and innovative ultrasound system, designed to meet new imaging needs when screening, diagnosing and monitoring major diseases.”

Discussed in more than 400 publications, the ShearWave™ Elastography (SWE™) technology employed in the Ultimate has demonstrated its clinical advantages for the detection and characterisation of many different diseases:

  • In the breast, Aixplorer Ultimate helps to improve the identification of malignant or benign lesions and to reduce the number of negative biopsies. The advantages of SWE in the diagnosis of breast lesions have been demonstrated in more than 300 publications. When this technology is combined with conventional ultrasound, diagnoses can be more accurate, significantly reducing the number of false positives, and thus the number of unnecessary biopsies.
  • In the liver, Aixplorer Ultimate can assess levels of fibrosis and NASH without a biopsy, as demonstrated in more than 100 international articles. SWE makes it possible to quantify liver stiffness in a non-invasive manner. Liver stiffness is a key parameter when diagnosing, assessing and monitoring liver fibrosis.
  • In the prostate, Aixplorer Ultimate provides effective guidance for biopsies. Clinical studies show that SWE considerably increases biopsy efficiency. Its colour mapping helps doctors target sampling and keep the number of samples to a minimum.
  • SWE is also frequently used in musculoskeletal imaging to view muscles, tendons, ligaments and joints, for the purposes of tendinopathy diagnosis and monitoring.
  • Aixplorer Ultimate’s technology is also very effective in vascular and pediatric examinations.

Attendees of AIUM 2018 are invited to visit SuperSonic Imagine at Booth #104 for a demo of Aixplorer Ultimate and additional live demonstrations with a model on the second floor of the exhibit hall. All demos will include Aixplorer Ultimate’s exclusive scanning modes, such as SWE, which is used to view and measure tissue stiffness in real time using color mapping; Needle PL.U.S, which enables precise real-time visualization of anatomical structures, biopsy needles and their trajectory; Angio PL.U.S., which offers unrivalled resolution for imaging microvascularization in lesions; and TriVu (Mode-B + SWE + Angio PL.U.S), three tests combined in a single examination.

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), Supersonic Imagine is a company that specialises in medical imaging. The company designs, develops and markets a revolutionary ultrasound platform, Aixplorer®, which uses the UltraFast™ technology that can acquire images around 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology gave rise to several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler technology, Angio PL.U.S – Planewave UltraSensitive™ Imaging, TriVu and, more recently Needle PL.U.S. ShearWave Elastography allows physicians to visualise and analyse the stiffness of tissue in real-time using a reliable, reproducible and non-invasive procedure. This is an important parameter in diagnosing potentially malignant lesions or other diseased tissue. As of today, over 300 publications have demonstrated the value of SWE in the care of patients with a wide range of diseases. The UltraFast Doppler combines colour flow imaging and pulsed wave Doppler into one simple test, providing physicians with the results of both simultaneously, therefore enhancing efficiency. The latest innovation, Angio PL.U.S, provides a higher level of microvascular imaging through significantly improved colour sensitivity and spatial resolution, while maintaining exceptional 2D image quality. SuperSonic Imagine has been granted regulatory clearances for the commercialisation of Aixplorer® on the main markets. Since April 2014, the SuperSonic Imagine company has been listed on Euronext (symbol: SSI).

Contact information

SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella
emmanuelle.vella@supersonicimagine.com
+33 4 86 79 03 27

FP2COM
Media Relations - EU
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 76 82 83
NewCap
Investor Relations – EU
Pierre Laurent / Florent Alba
supersonicimagine@newcap.fr
+33 1 44 71 98 55

Pascale Communication
Media Relations - US
Amy Phillips
amy@pascalecommunications.com
+1 412 327 9499

 

GlobeNewswire
globenewswire.com

Last updated on: 21/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.